Anlon Healthcare Ltd has issued a formal disclosure addressing BSE and NSE queries regarding its preferential share swap. The company confirmed an issue price of Rs 17.85 per share, supported by a revised independent valuation report and a comprehensive list of beneficial owners. This update ensures compliance with SEBI (ICDR) regulations following shareholder approval at the September 5 AGM, facilitating the planned acquisition of stakes in Apiqo Organics and Bizotic Lifescience.
Anlon Healthcare Clarifies Preferential Share Pricing
Issue price fixed at Rs 17.85 per share; list of 26 allottees disclosed for regulatory transparency.
Reader Takeaway: The disclosure addresses exchange-raised compliance queries, finalizing the pricing and ownership details for the approved share swap.
What just happened
Anlon Healthcare Ltd has filed a formal clarification in response to observations from the BSE and NSE regarding its proposed preferential share swap. This disclosure acts as an addendum to the company’s recent AGM notices, specifically addressing regulatory concerns regarding the pricing methodology and transparency of the allottees.
Why this matters
The company has firmly established the issue price at Rs 17.85 per share. This price was determined based on the higher of the volume-weighted average prices (VWAP) as required under SEBI (ICDR) regulations. By providing an updated valuation report from an independent registered valuer, CA Gaurang Agarwal, the company aims to eliminate ambiguity regarding the valuation of the share swap deal.
The backstory
At the Annual General Meeting held on September 5, 2026, shareholders approved a plan for Anlon Healthcare to acquire a 44.94% stake in Apiqo Organics Private Limited and a 47.41% stake in Bizotic Lifescience Private Limited. Following this, both the BSE and NSE sought further disclosures on September 10 and 11, 2026, to ensure complete transparency before the allotment process moves forward.
What changes now
With the disclosure of the list of 26 proposed allottees and their beneficial owners, the company has cleared the primary compliance hurdle. Shareholders and prospective investors can now view the detailed rationale and ownership structures on the company's official website under the 'Investors' portal.
What to track next
Investors should monitor the official allotment process as it proceeds to completion. The successful integration of the acquired stakes in Apiqo Organics and Bizotic Lifescience remains the key operational milestone for the company following this share issuance.